Credit Suisse’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Credit Suisse’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-12,313	Closed	-$42K	–	4036
2017 Q1	$42K	Sell	12,313 -1,866	-13%	-$8.82K	﹤0.01%	3755
2016 Q4	$73K	Buy	14,179 +11,751	+484%	+$203K	﹤0.01%	3988
2016 Q3	$61K	Sell	2,428 -497	-17%	-$12.5K	﹤0.01%	3997
2016 Q2	$73K	Buy	2,925 +606	+26%	+$17.1K	﹤0.01%	4106
2016 Q1	$68K	Sell	2,319 -7,078	-75%	-$192K	﹤0.01%	3870
2015 Q4	$349K	Buy	9,397 +5,056	+116%	+$223K	﹤0.01%	3609
2015 Q3	$212K	Sell	4,341 -606	-12%	-$42.3K	﹤0.01%	3902
2015 Q2	$341K	Buy	+4,947	New	+$229K	﹤0.01%	3952
2015 Q1	–	Sell	-4,000	Closed	-$51K	–	4701
2014 Q4	$51K	Sell	4,000 -19	-0.5%	-$276	﹤0.01%	4519
2014 Q3	$61K	Buy	+4,019	New	+$84.6K	﹤0.01%	4347

Other funds holding ANTH

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Credit Suisse's ANTH Position: Q2 2017 in Review

Credit Suisse sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 12,313 shares — an estimated $42K sold.

Credit Suisse first reported a position in ANTH in Q3 2014 and held it in 10 quarters. The position peaked at $349K in Q4 2015. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

Credit Suisse reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
Credit Suisse sold 12,313 Anthera Pharmaceuticals, Inc. shares in Q2 2017, an estimated $42K.
Credit Suisse first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2014 and held it in 10 quarters.
Credit Suisse's Anthera Pharmaceuticals, Inc. position peaked at $349K in Q4 2015.
40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on Credit Suisse's 13F filing for Q2 2017, filed 14 Aug 2017.